{
    "id": 29160,
    "fullName": "ERBB3 F94L",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) F94L lies within the extracellular domain of the Erbb3 (Her3) protein (PMID: 29963236). The functional effect of F94L is conflicting as it does not result in increased cell proliferation relative to wild-type Erbb3 (Her3) in ER-positive breast cancer cells, but leads to elevated cell proliferation when expressed in Erbb2 (Her2)-overexpressing cells in culture (PMID: 29963236), and therefore, its effect on Erbb3 (Her3) protein function is unknown.",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "F94L",
    "createDate": "01/04/2019",
    "updateDate": "09/28/2019",
    "referenceTranscriptCoordinates": {
        "id": 177832,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56085040T>C",
        "cDna": "c.280T>C",
        "protein": "p.F94L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Nerlynx (neratinib) resulted in reduced colony formation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) F94L in culture relative to control treatment, however, at a much greater concentration than the minimal concentration required for ERBB2 (HER2) activating mutations (PMID: 29963236).",
            "molecularProfile": {
                "id": 31128,
                "profileName": "ERBB2 over exp ERBB3 F94L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15641,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Herceptin (trastuzumab) and Perjeta (pertuzumab) did not result in reduced colony formation in ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) F94L in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31128,
                "profileName": "ERBB2 over exp ERBB3 F94L"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15651,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) did not lead to reduced proliferation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) F94L in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31128,
                "profileName": "ERBB2 over exp ERBB3 F94L"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Perjeta (pertuzumab) did not result in reduced colony formation in ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) F94L in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31128,
                "profileName": "ERBB2 over exp ERBB3 F94L"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31096,
            "profileName": "ERBB3 F94L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31128,
            "profileName": "ERBB2 over exp ERBB3 F94L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177833,
            "transcript": "NM_001005915",
            "gDna": "chr12:g.56085040T>C",
            "cDna": "c.280T>C",
            "protein": "p.F94L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 177832,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56085040T>C",
            "cDna": "c.280T>C",
            "protein": "p.F94L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}